SAROS changes https://saros.gcarosso.bio/ Registry and regulatory changes since the 2026-10-19 snapshot: slipped, firmed and new trials, status changes, moved PDUFA dates. Public sources only. 2026-10-22T15:18:52.035568Z STATUS · A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravishttps://saros.gcarosso.bio/#t=NCT07622342NCT07622342:status:2026-10-22Guangdong Hengrui Pharmaceutical Co., Ltd · status: NOT_YET_RECRUITING → RECRUITING FIRMED · A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crhttps://saros.gcarosso.bio/#t=NCT07222189NCT07222189:firmed:2026-10-22Sanofi · primary completion: 2026-09-30 → 2026-09-29; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; enrollment: 325 → 7; why stopped: → Business decision FIRMED · A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chrohttps://saros.gcarosso.bio/#t=NCT07446491NCT07446491:firmed:2026-10-22Chongqing Peg-Bio Biopharm Co., Ltd. · primary completion: 2026-05-30 → 2026-10-10; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED NEW · A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Shttps://saros.gcarosso.bio/#t=NCT07890324NCT07890324:new:2026-10-22Jiangsu Guiqiong Pharmaceutical Co., Ltd. · new in the registry STATUS · A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)https://saros.gcarosso.bio/#t=NCT07821944NCT07821944:status:2026-10-22Merck Sharp & Dohme LLC · status: NOT_YET_RECRUITING → RECRUITING NEW · A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.https://saros.gcarosso.bio/#t=NCT07882472NCT07882472:new:2026-10-22Dignify Therapeutics · new in the registry STATUS · Postsurgical Analgesia After Unilateral Bunionectomyhttps://saros.gcarosso.bio/#t=NCT07858734NCT07858734:status:2026-10-22AmacaThera Inc. · status: RECRUITING → NOT_YET_RECRUITING CHANGED · An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Parthttps://saros.gcarosso.bio/#t=NCT07503886NCT07503886:changed:2026-10-22Dompé Farmaceutici S.p.A · primary completion: 2027-01-24 → 2026-12-27 STATUS · A Study to Test CRT-402 in Refractory Autoimmune Diseasehttps://saros.gcarosso.bio/#t=NCT07778446NCT07778446:status:2026-10-22Myeloid Therapeutics · status: NOT_YET_RECRUITING → RECRUITING NEW · A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.https://saros.gcarosso.bio/#t=NCT07889245NCT07889245:new:2026-10-22Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. · new in the registry SLIPPED · A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therahttps://saros.gcarosso.bio/#t=NCT06055439NCT06055439:slipped:2026-10-22Chimeric Therapeutics · primary completion: 2026-05 → 2026-12-31; status: RECRUITING → ACTIVE_NOT_RECRUITING SLIPPED · Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Bodyhttps://saros.gcarosso.bio/#t=NCT07753252NCT07753252:slipped:2026-10-22Bayer · primary completion: 2026-09-21 → 2026-10-22; status: NOT_YET_RECRUITING → RECRUITING CHANGED · Study of ALXN2220 Versus Placebo in Adults With ATTR-CMhttps://saros.gcarosso.bio/#t=NCT06183931NCT06183931:changed:2026-10-22Alexion Pharmaceuticals, Inc. · enrollment: 1181 → 1182 NEW · Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Paphttps://saros.gcarosso.bio/#t=NCT07888686NCT07888686:new:2026-10-22Serum Institute of India Pvt. Ltd. · new in the registry NEW · A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebhttps://saros.gcarosso.bio/#t=NCT07889492NCT07889492:new:2026-10-22Edesa Biotech Inc. · new in the registry NEW · WST03 Capsule Combined With Metronidazole for Bacterial Vaginosishttps://saros.gcarosso.bio/#t=NCT07888699NCT07888699:new:2026-10-22SPH Sine Pharmaceutical Laboratories Co., Ltd. · new in the registry CHANGED · Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgahttps://saros.gcarosso.bio/#t=NCT07457918NCT07457918:changed:2026-10-22Verrica Pharmaceuticals Inc. · primary completion: 2028-04-30 → 2027-11; enrollment: 600 → 250 STATUS · A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumoniahttps://saros.gcarosso.bio/#t=NCT06841731NCT06841731:status:2026-10-22Jiangsu HengRui Medicine Co., Ltd. · status: ACTIVE_NOT_RECRUITING → COMPLETED CHANGED · To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitihttps://saros.gcarosso.bio/#t=NCT07620366NCT07620366:changed:2026-10-22Qilu Pharmaceutical Co., Ltd. · primary outcome text: Changes in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 24 relative to baseline → Changes in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 12 relative to baseline SLIPPED · PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Chttps://saros.gcarosso.bio/#t=NCT06616532NCT06616532:slipped:2026-10-22Biotheus Inc. · primary completion: 2027-01-25 → 2027-05 SLIPPED · INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diahttps://saros.gcarosso.bio/#t=NCT03491683NCT03491683:slipped:2026-10-22Inovio Pharmaceuticals · primary completion: 2026-12-31 → 2027-12-31 STATUS · A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancerhttps://saros.gcarosso.bio/#t=NCT06792695NCT06792695:status:2026-10-22AstraZeneca · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 80 → 82 STATUS · A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Diseasehttps://saros.gcarosso.bio/#t=NCT06881836NCT06881836:status:2026-10-22Ono Pharmaceutical Co., Ltd. · status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)https://saros.gcarosso.bio/#t=NCT07889193NCT07889193:new:2026-10-22Sinovac Biotech Co., Ltd · new in the registry NEW · A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Whttps://saros.gcarosso.bio/#t=NCT07890376NCT07890376:new:2026-10-22Eli Lilly and Company · new in the registry FIRMED · A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmahttps://saros.gcarosso.bio/#t=NCT07345364NCT07345364:firmed:2026-10-22Jiangsu Simcere Pharmaceutical Co., Ltd. · primary completion: 2026-07-30 → 2026-06-18; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 72 → 64 FIRMED · A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Bhttps://saros.gcarosso.bio/#t=NCT06965465NCT06965465:firmed:2026-10-22Pfizer · date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED FIRMED · A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients Whttps://saros.gcarosso.bio/#t=NCT06295432NCT06295432:firmed:2026-10-22Dizal Pharmaceuticals · primary completion: 2026-12 → 2026-06-08; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 90 → 30 NEW · Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gouthttps://saros.gcarosso.bio/#t=NCT07889284NCT07889284:new:2026-10-22ScandiBio Therapeutics AB · new in the registry NEW · Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapyhttps://saros.gcarosso.bio/#t=NCT07890350NCT07890350:new:2026-10-22Beijing Keymed Biosciences Co., Ltd. · new in the registry FIRMED · A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (https://saros.gcarosso.bio/#t=NCT06356311NCT06356311:firmed:2026-10-22Merck Sharp & Dohme LLC · primary completion: 2027-01-04 → 2026-10-19; date type: ESTIMATED → ACTUAL; enrollment: 450 → 473 CHANGED · A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advancedhttps://saros.gcarosso.bio/#t=NCT04420884NCT04420884:changed:2026-10-22Takeda · primary outcome text: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity → Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Grade 3 or Higher TEAEs STATUS · A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHDhttps://saros.gcarosso.bio/#t=NCT05643638NCT05643638:status:2026-10-22Cynata Therapeutics Limited · status: ACTIVE_NOT_RECRUITING → TERMINATED; enrollment: 60 → 65; why stopped: → Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in com SLIPPED · Study of CHO-A04 in Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07049458NCT07049458:slipped:2026-10-22Cho Pharma Inc. · primary completion: 2027-10-01 → 2028-12-01 FIRMED · Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutritionhttps://saros.gcarosso.bio/#t=NCT06512584NCT06512584:firmed:2026-10-22Chongqing Peg-Bio Biopharm Co., Ltd. · primary completion: 2026-03-30 → 2026-09-28; date type: ESTIMATED → ACTUAL; status: RECRUITING → ACTIVE_NOT_RECRUITING FIRMED · A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Followinghttps://saros.gcarosso.bio/#t=NCT07412496NCT07412496:firmed:2026-10-22Bausch & Lomb Incorporated · primary completion: 2027-02 → 2026-10-04; date type: ESTIMATED → ACTUAL; status: NOT_YET_RECRUITING → COMPLETED; enrollment: 123 → 130 STATUS · Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF https://saros.gcarosso.bio/#t=NCT07347197NCT07347197:status:2026-10-22Heartseed Inc. · status: NOT_YET_RECRUITING → RECRUITING SLIPPED · Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-pohttps://saros.gcarosso.bio/#t=NCT04784715NCT04784715:slipped:2026-10-22AstraZeneca · primary completion: 2026-11-11 → 2027-05-03 SLIPPED · A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Partihttps://saros.gcarosso.bio/#t=NCT06650852NCT06650852:slipped:2026-10-22Brii Biosciences Limited · primary completion: 2026-07 → 2028-09 NEW · A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participanthttps://saros.gcarosso.bio/#t=NCT07889349NCT07889349:new:2026-10-22Beijing Suncadia Pharmaceuticals Co., Ltd · new in the registry NEW · Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adultshttps://saros.gcarosso.bio/#t=NCT07888088NCT07888088:new:2026-10-22Bavarian Nordic · new in the registry STATUS · A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV)https://saros.gcarosso.bio/#t=NCT07785843NCT07785843:status:2026-10-22Merck Sharp & Dohme LLC · status: NOT_YET_RECRUITING → RECRUITING NEW · Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M https://saros.gcarosso.bio/#t=NCT07890454NCT07890454:new:2026-10-22Sanofi · new in the registry NEW · Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAhttps://saros.gcarosso.bio/#t=NCT07888569NCT07888569:new:2026-10-22Dizal Pharmaceuticals · new in the registry NEW · OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients Whttps://saros.gcarosso.bio/#t=NCT07888075NCT07888075:new:2026-10-22AVEO Pharmaceuticals, Inc. · new in the registry SLIPPED · A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and https://saros.gcarosso.bio/#t=NCT05440708NCT05440708:slipped:2026-10-22Tvardi Therapeutics, Incorporated · primary completion: 2027-02-01 → 2027-05-25 NEW · A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.https://saros.gcarosso.bio/#t=NCT07890870NCT07890870:new:2026-10-22iBio, Inc. · new in the registry NEW · A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIShttps://saros.gcarosso.bio/#t=NCT07890298NCT07890298:new:2026-10-22Lumosa Therapeutics Co., Ltd. · new in the registry FIRMED · A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge Withttps://saros.gcarosso.bio/#t=NCT07198139NCT07198139:firmed:2026-10-22Cocrystal Pharma, Inc. · primary completion: 2026-10-01 → 2026-09-14; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 40 → 32 SLIPPED · A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphomahttps://saros.gcarosso.bio/#t=NCT03952078NCT03952078:slipped:2026-10-22Corvus Pharmaceuticals, Inc. · primary completion: 2026-04-30 → 2026-12-30 NEW · A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprhttps://saros.gcarosso.bio/#t=NCT07890909NCT07890909:new:2026-10-22Vertex Pharmaceuticals Incorporated · new in the registry STATUS · A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Diseasehttps://saros.gcarosso.bio/#t=NCT07787182NCT07787182:status:2026-10-22Eli Lilly and Company · status: NOT_YET_RECRUITING → RECRUITING STATUS · Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)https://saros.gcarosso.bio/#t=NCT07162883NCT07162883:status:2026-10-22Qilu Pharmaceutical Co., Ltd. · status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 122 → 146 STATUS · A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhttps://saros.gcarosso.bio/#t=NCT07688772NCT07688772:status:2026-10-22Guangdong Hengrui Pharmaceutical Co., Ltd · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 196 → 220 STATUS · A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Ihttps://saros.gcarosso.bio/#t=NCT07827599NCT07827599:status:2026-10-22Hoffmann-La Roche · status: NOT_YET_RECRUITING → RECRUITING NEW · A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07887971NCT07887971:new:2026-10-22Aktis Oncology, Inc. · new in the registry SLIPPED · Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseaseshttps://saros.gcarosso.bio/#t=NCT06626919NCT06626919:slipped:2026-10-22Kite, A Gilead Company · primary completion: 2027-03 → 2028-10; primary outcome text: Assess safety profile, including any DLT and MTD (if applicable) → Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE) NEW · A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)https://saros.gcarosso.bio/#t=NCT07222488NCT07222488:new:2026-10-22Merck Sharp & Dohme LLC · new in the registry NEW · A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabeteshttps://saros.gcarosso.bio/#t=NCT07889505NCT07889505:new:2026-10-22Pharmasaga Co. Ltd. · new in the registry STATUS · Safety, Tolerability, PK, and PD of TGM-148 in Healthy Participantshttps://saros.gcarosso.bio/#t=NCT07843368NCT07843368:status:2026-10-22Tangram Therapeutics Plc · status: NOT_YET_RECRUITING → RECRUITING NEW · A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (https://saros.gcarosso.bio/#t=NCT07889362NCT07889362:new:2026-10-22Biogen · new in the registry SLIPPED · IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)https://saros.gcarosso.bio/#t=NCT06940440NCT06940440:slipped:2026-10-21TuHURA Biosciences, Inc. · primary completion: 2026-05-31 → 2027-04 NEW · A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficienhttps://saros.gcarosso.bio/#t=NCT07887347NCT07887347:new:2026-10-21Prime Medicine, Inc. · new in the registry FIRMED · Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Streshttps://saros.gcarosso.bio/#t=NCT03104517NCT03104517:firmed:2026-10-21Cook MyoSite · primary completion: 2026-09 → 2026-06-11; date type: ESTIMATED → ACTUAL FIRMED · A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participanthttps://saros.gcarosso.bio/#t=NCT06834347NCT06834347:firmed:2026-10-21Sanofi · primary completion: 2026-10-14 → 2026-09-23; date type: ESTIMATED → ACTUAL FIRMED · A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Sohttps://saros.gcarosso.bio/#t=NCT05382325NCT05382325:firmed:2026-10-21Merck Sharp & Dohme LLC · primary completion: 2026-09-30 → 2026-09-29; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; enrollment: 70 → 30; why stopped: → Business Reasons FIRMED · Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteershttps://saros.gcarosso.bio/#t=NCT07254325NCT07254325:firmed:2026-10-21Taizhou Mabtech Pharmaceutical Co.,Ltd · primary completion: 2026-06-01 → 2026-06-12; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participantshttps://saros.gcarosso.bio/#t=NCT07884864NCT07884864:new:2026-10-21Ausper Biopharma Co., Ltd. · new in the registry FIRMED · Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating https://saros.gcarosso.bio/#t=NCT06491563NCT06491563:firmed:2026-10-21Brii Biosciences Limited · primary completion: 2026-12 → 2026-08-05; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participantshttps://saros.gcarosso.bio/#t=NCT07887763NCT07887763:new:2026-10-21Bristol-Myers Squibb · new in the registry NEW · Study of the Safety, Tolerability, Pharmacokinetics of VV147 Tablets in Chinese Healthy Participants.https://saros.gcarosso.bio/#t=NCT07885202NCT07885202:new:2026-10-21Vigonvita Life Sciences · new in the registry STATUS · A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adultshttps://saros.gcarosso.bio/#t=NCT07697846NCT07697846:status:2026-10-21Beijing QL Biopharmaceutical Co.,Ltd · status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING CHANGED · Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLhttps://saros.gcarosso.bio/#t=NCT04404283NCT04404283:changed:2026-10-21Seagen, a wholly owned subsidiary of Pfizer · enrollment: 239 → 240; primary outcome text: Overall survival (OS) → Overall Survival (OS) SLIPPED · A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Particihttps://saros.gcarosso.bio/#t=NCT07735637NCT07735637:slipped:2026-10-21AstraZeneca · primary completion: 2028-10-11 → 2028-11-02; status: NOT_YET_RECRUITING → RECRUITING CHANGED · A Study of JNT-517 in Participants With Phenylketonuria (PKU)https://saros.gcarosso.bio/#t=NCT06971731NCT06971731:changed:2026-10-21Otsuka Pharmaceutical Development & Commercialization, Inc. · primary outcome text: Absolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 150 mg BID Dose Group at End of Period 1 → Absolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Dose Group at End of Period 1 STATUS · A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitishttps://saros.gcarosso.bio/#t=NCT06867094NCT06867094:status:2026-10-21Sanofi · status: ACTIVE_NOT_RECRUITING → TERMINATED; enrollment: 204 → 170; why stopped: → Business decision CHANGED · A Study Testing the Safety and Effects of FB102 in Healthy Volunteershttps://saros.gcarosso.bio/#t=NCT07623057NCT07623057:changed:2026-10-21Forte Biosciences, Inc. · enrollment: 48 → 64 NEW · Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anfibatide Injection in Healthhttps://saros.gcarosso.bio/#t=NCT07887490NCT07887490:new:2026-10-21Lee's Pharmaceutical Limited · new in the registry FIRMED · A Clinical Study of YTS109 Cell for R/R Autoimmune Diseaseshttps://saros.gcarosso.bio/#t=NCT07104721NCT07104721:firmed:2026-10-21China Immunotech (Beijing) Biotechnology Co., Ltd. · date type: ESTIMATED → ACTUAL STATUS · A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doseshttps://saros.gcarosso.bio/#t=NCT07280936NCT07280936:status:2026-10-21Beijing Suncadia Pharmaceuticals Co., Ltd · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 124 → 76 STATUS · A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safetyhttps://saros.gcarosso.bio/#t=NCT07876076NCT07876076:status:2026-10-21Adaxion Therapeutics · status: NOT_YET_RECRUITING → RECRUITING CHANGED · Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancerhttps://saros.gcarosso.bio/#t=NCT05168566NCT05168566:changed:2026-10-21Teligene US · enrollment: 99 → 128 CHANGED · A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.https://saros.gcarosso.bio/#t=NCT07099430NCT07099430:changed:2026-10-21Nanjing Leads Biolabs Co.,Ltd · enrollment: 200 → 280 FIRMED · Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bhttps://saros.gcarosso.bio/#t=NCT06510374NCT06510374:firmed:2026-10-21Ferring Pharmaceuticals · primary completion: 2028-06-30 → 2028-09-30 NEW · A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participantshttps://saros.gcarosso.bio/#t=NCT07884734NCT07884734:new:2026-10-21GRIN Therapeutics, Inc. · new in the registry NEW · IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathyhttps://saros.gcarosso.bio/#t=NCT07886476NCT07886476:new:2026-10-21Innovent Biologics (Suzhou) Co. Ltd. · new in the registry SLIPPED · A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastahttps://saros.gcarosso.bio/#t=NCT06279364NCT06279364:slipped:2026-10-21Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · primary completion: 2026-07 → 2027-04; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 524 → 537 STATUS · Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participantshttps://saros.gcarosso.bio/#t=NCT07550816NCT07550816:status:2026-10-21Beijing QL Biopharmaceutical Co.,Ltd · status: RECRUITING → ACTIVE_NOT_RECRUITING SLIPPED · A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseaseshttps://saros.gcarosso.bio/#t=NCT07123519NCT07123519:slipped:2026-10-21China Immunotech (Beijing) Biotechnology Co., Ltd. · primary completion: 2026-08-13 → 2027-08-13 STATUS · A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Diseasehttps://saros.gcarosso.bio/#t=NCT07094516NCT07094516:status:2026-10-21Novartis Pharmaceuticals · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 407 → 97 STATUS · A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-66https://saros.gcarosso.bio/#t=NCT07779798NCT07779798:status:2026-10-21Crossbow Therapeutics, Inc. · status: NOT_YET_RECRUITING → RECRUITING FIRMED · A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esohttps://saros.gcarosso.bio/#t=NCT07037875NCT07037875:firmed:2026-10-21Cinclus Pharma Holding AB · primary completion: 2026-08 → 2026-09-28; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED; enrollment: 500 → 523 FIRMED · Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutatihttps://saros.gcarosso.bio/#t=NCT05358249NCT05358249:firmed:2026-10-21Novartis Pharmaceuticals · primary completion: 2026-09-30 → 2026-09-28; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → Business reasons and not based on any safety concerns. FIRMED · Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)https://saros.gcarosso.bio/#t=NCT06880081NCT06880081:firmed:2026-10-21Chongqing Peg-Bio Biopharm Co., Ltd. · primary completion: 2026-02-27 → 2026-02-14; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED SLIPPED · Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopahttps://saros.gcarosso.bio/#t=NCT07264270NCT07264270:slipped:2026-10-21Consano Bio · primary completion: 2026-11-01 → 2027-06 CHANGED · Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancerhttps://saros.gcarosso.bio/#t=NCT05997615NCT05997615:changed:2026-10-21Astellas Pharma Global Development, Inc. · primary completion: 2027-09-29 → 2027-09-30; enrollment: 437 → 347; primary outcome text: All parts: Incidence of treatment emergent anti-drug antibodies (ADAs) to VIR-5500 → Part 1, 1a, 2a and Part 3: Number of Participants With Adverse Events (AEs) (mCRPC, mHSPC and BRPC) NEW · Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patientshttps://saros.gcarosso.bio/#t=NCT06740149NCT06740149:new:2026-10-21GuangZhou Cellgenes Biotechnology Co., Ltd. · new in the registry NEW · Prevention of COVID-19 Infection to Severe Pneumonia or ARDShttps://saros.gcarosso.bio/#t=NCT04569227NCT04569227:new:2026-10-21Enzychem Lifesciences Corporation · new in the registry SLIPPED · Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthmahttps://saros.gcarosso.bio/#t=NCT07120503NCT07120503:slipped:2026-10-21Windward Bio · primary completion: 2027-07 → 2028-10-01; status: ACTIVE_NOT_RECRUITING → RECRUITING; enrollment: 136 → 600; primary outcome text: Number of participants with treatment-emergent adverse events (TEAEs) during the study → PART A: Number of participants with treatment-emergent adverse events (TEAEs) during the study SLIPPED · Leading in MPNs Beyond Ruxolitinib in Combo With T-Regshttps://saros.gcarosso.bio/#t=NCT05423691NCT05423691:slipped:2026-10-21Cellenkos, Inc. · primary completion: 2026-04-30 → 2027-04-30 SLIPPED · Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT06933069NCT06933069:slipped:2026-10-21Taizhou Mabtech Pharmaceutical Co.,Ltd · primary completion: 2026-05-31 → 2027-05-31 SLIPPED · A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methhttps://saros.gcarosso.bio/#t=NCT06721494NCT06721494:slipped:2026-10-21Clear Scientific, Inc. · primary completion: 2026-09-04 → 2026-10-29 NEW · Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Diseasehttps://saros.gcarosso.bio/#t=NCT07885605NCT07885605:new:2026-10-21Ethyreal Bio, Inc. · new in the registry NEW · Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Phttps://saros.gcarosso.bio/#t=NCT05294731NCT05294731:new:2026-10-21BeOne Medicines · new in the registry FIRMED · Aleniglipron Phase 2 in Type 2 Diabetes Mellitushttps://saros.gcarosso.bio/#t=NCT07400588NCT07400588:firmed:2026-10-21Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · primary completion: 2026-09 → 2026-09-18; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED STATUS · A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic https://saros.gcarosso.bio/#t=NCT07227103NCT07227103:status:2026-10-21NeuroRx, Inc. · status: NOT_YET_RECRUITING → RECRUITING; enrollment: 400 → 240 NEW · Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT07885267NCT07885267:new:2026-10-21Antido Therapeutics (Australia) Pty Ltd · new in the registry NEW · LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)https://saros.gcarosso.bio/#t=NCT07886554NCT07886554:new:2026-10-21IRulya Therapeutics Inc. · new in the registry STATUS · An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibitihttps://saros.gcarosso.bio/#t=NCT07855250NCT07855250:status:2026-10-21Sanofi · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · A Study to Evaluate the Efficacy and Safety of TP-06 for PCEDhttps://saros.gcarosso.bio/#t=NCT07886268NCT07886268:new:2026-10-21Tarsus Pharmaceuticals, Inc. · new in the registry STATUS · A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urhttps://saros.gcarosso.bio/#t=NCT06857175NCT06857175:status:2026-10-21Sichuan Baili Pharmaceutical Co., Ltd. · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 508 → 515 FIRMED · A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participanthttps://saros.gcarosso.bio/#t=NCT06834360NCT06834360:firmed:2026-10-21Sanofi · primary completion: 2026-11-06 → 2026-09-24; date type: ESTIMATED → ACTUAL STATUS · A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or Wihttps://saros.gcarosso.bio/#t=NCT06507904NCT06507904:status:2026-10-21Pfizer · primary completion: 2027-02-19 → 2027-02-08; status: NOT_YET_RECRUITING → RECRUITING SLIPPED · First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mhttps://saros.gcarosso.bio/#t=NCT05099172NCT05099172:slipped:2026-10-21Bayer · primary completion: 2026-03-16 → 2028-12-01; date type: ACTUAL → ESTIMATED FIRMED · Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013https://saros.gcarosso.bio/#t=NCT07499908NCT07499908:firmed:2026-10-21Citryll BV · primary completion: 2026-08-15 → 2026-08-10; date type: ESTIMATED → ACTUAL; status: NOT_YET_RECRUITING → COMPLETED; primary outcome text: Safety and tolerability → Incidence of Treatment-Emergent Adverse Events SLIPPED · Regulatory T Cells for Amyotrophic Lateral Sclerosishttps://saros.gcarosso.bio/#t=NCT05695521NCT05695521:slipped:2026-10-21Cellenkos, Inc. · primary completion: 2026-05 → 2027-05 CHANGED · Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)https://saros.gcarosso.bio/#t=NCT07596784NCT07596784:changed:2026-10-21Alexion Pharmaceuticals, Inc. · primary completion: 2027-08-17 → 2027-08-24 NEW · Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-https://saros.gcarosso.bio/#t=NCT07885891NCT07885891:new:2026-10-21Wockhardt · new in the registry STATUS · A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participanthttps://saros.gcarosso.bio/#t=NCT07443059NCT07443059:status:2026-10-21Beijing QL Biopharmaceutical Co.,Ltd · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or https://saros.gcarosso.bio/#t=NCT07399704NCT07399704:new:2026-10-21Azafaros B.V. · new in the registry CHANGED · Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Withttps://saros.gcarosso.bio/#t=NCT06989840NCT06989840:changed:2026-10-21Sagimet Biosciences Inc. · enrollment: 128 → 152 STATUS · Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Herhttps://saros.gcarosso.bio/#t=NCT07332091NCT07332091:status:2026-10-21CSL Behring · status: RECRUITING → ACTIVE_NOT_RECRUITING FIRMED · A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimhttps://saros.gcarosso.bio/#t=NCT06487559NCT06487559:firmed:2026-10-21AbbVie · primary completion: 2027-02 → 2026-09-18; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → Strategic considerations SLIPPED · Phase 3 Bunionectomy Studyhttps://saros.gcarosso.bio/#t=NCT07490496NCT07490496:slipped:2026-10-21Cali Pharmaceuticals LLC · primary completion: 2026-10-30 → 2027-06-30 STATUS · A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combinahttps://saros.gcarosso.bio/#t=NCT06952478NCT06952478:status:2026-10-21Celltrion · primary completion: 2027-11-15 → 2027-03-08; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 486 → 473 SLIPPED · A Clinical Study of YTS109 Cell in R/R Autoimmune Diseaseshttps://saros.gcarosso.bio/#t=NCT06978647NCT06978647:slipped:2026-10-21China Immunotech (Beijing) Biotechnology Co., Ltd. · primary completion: 2026-05-19 → 2027-05-19 STATUS · A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenohttps://saros.gcarosso.bio/#t=NCT07658183NCT07658183:status:2026-10-21Shanghai Best-Link Bioscience, LLC · status: NOT_YET_RECRUITING → RECRUITING NEW · Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2https://saros.gcarosso.bio/#t=NCT05522231NCT05522231:new:2026-10-20Hutchmed · new in the registry STATUS · A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemhttps://saros.gcarosso.bio/#t=NCT05259709NCT05259709:status:2026-10-20Regeneron Pharmaceuticals · primary completion: 2027-05-05 → 2027-04-29; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 50 → 22 SLIPPED · Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participantshttps://saros.gcarosso.bio/#t=NCT06577337NCT06577337:slipped:2026-10-20Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · primary completion: 2026-11-16 → 2027-12-18; status: RECRUITING → SUSPENDED; why stopped: → The study is currently paused pending a potential amendment. STATUS · PSMA PET Combined With MRI for the Detection of PCahttps://saros.gcarosso.bio/#t=NCT07052214NCT07052214:status:2026-10-20Telix Pharmaceuticals (Innovations) Pty Limited · status: RECRUITING → ACTIVE_NOT_RECRUITING STATUS · A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravethttps://saros.gcarosso.bio/#t=NCT06872125NCT06872125:status:2026-10-20Stoke Therapeutics, Inc · status: RECRUITING → ACTIVE_NOT_RECRUITING STATUS · A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosishttps://saros.gcarosso.bio/#t=NCT07260669NCT07260669:status:2026-10-20Gesynta Pharma AB · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 190 → 213 STATUS · Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelohttps://saros.gcarosso.bio/#t=NCT07672769NCT07672769:status:2026-10-20Faron Pharmaceuticals Ltd · primary completion: 2027-11-30 → 2027-11; status: NOT_YET_RECRUITING → RECRUITING; primary outcome text: Dose selection utility score 3-months from last participant enrollment utilising efficacy and safety components. → Dose selection utility score utilising efficacy and safety components. FIRMED · Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapaglihttps://saros.gcarosso.bio/#t=NCT07754331NCT07754331:firmed:2026-10-20AstraZeneca · primary completion: 2026-12-03 → 2026-10-06; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED SLIPPED · TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patientshttps://saros.gcarosso.bio/#t=NCT06088888NCT06088888:slipped:2026-10-20Shenzhen TargetRx Co., Ltd. · primary completion: 2027-03-30 → 2027-12-31 NEW · A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.https://saros.gcarosso.bio/#t=NCT07883213NCT07883213:new:2026-10-20Akeso · new in the registry SLIPPED · An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participahttps://saros.gcarosso.bio/#t=NCT06589596NCT06589596:slipped:2026-10-20BeOne Medicines · primary completion: 2027-09-30 → 2028-08-31; enrollment: 525 → 695 STATUS · Clinical Study to Evaluate Remineralization Using an in Situ Model.https://saros.gcarosso.bio/#t=NCT07625670NCT07625670:status:2026-10-20Colgate Palmolive · status: NOT_YET_RECRUITING → ENROLLING_BY_INVITATION STATUS · Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Painhttps://saros.gcarosso.bio/#t=NCT07226258NCT07226258:status:2026-10-20Saol Therapeutics Inc · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participahttps://saros.gcarosso.bio/#t=NCT07818915NCT07818915:new:2026-10-20ViiV Healthcare · new in the registry STATUS · A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancerhttps://saros.gcarosso.bio/#t=NCT06623136NCT06623136:status:2026-10-20Elpiscience (Suzhou) Biopharma, Ltd. · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 40 → 30 NEW · RBD1119 in Coronary Artery Disease (CAD)https://saros.gcarosso.bio/#t=NCT07884136NCT07884136:new:2026-10-20Ribocure Pharmaceuticals AB · new in the registry FIRMED · Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knehttps://saros.gcarosso.bio/#t=NCT07338266NCT07338266:firmed:2026-10-20Avidence Therapeutics · primary completion: 2026-12 → 2027-05; enrollment: 15 → 20 NEW · Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Olderhttps://saros.gcarosso.bio/#t=NCT07883928NCT07883928:new:2026-10-20GC Biopharma Corp · new in the registry NEW · An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasishttps://saros.gcarosso.bio/#t=NCT07879885NCT07879885:new:2026-10-20Hansoh BioMedical R&D Company · new in the registry FIRMED · A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Nahttps://saros.gcarosso.bio/#t=NCT05879822NCT05879822:firmed:2026-10-20Incyte Corporation · date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → This was a strategic business decision. There were no safety concerns contributing to this decision. SLIPPED · Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Proshttps://saros.gcarosso.bio/#t=NCT06702995NCT06702995:slipped:2026-10-20Evopoint Biosciences Inc. · primary completion: 2026-05-13 → 2027-07-13 NEW · The First-in-Human Study of GW906 Injectionhttps://saros.gcarosso.bio/#t=NCT07884461NCT07884461:new:2026-10-20Shenzhen Salubris Pharmaceuticals Co., Ltd. · new in the registry STATUS · A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Diseasehttps://saros.gcarosso.bio/#t=NCT07822334NCT07822334:status:2026-10-20Hoffmann-La Roche · status: NOT_YET_RECRUITING → RECRUITING FIRMED · A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)https://saros.gcarosso.bio/#t=NCT06937749NCT06937749:firmed:2026-10-20Innovent Biologics (Suzhou) Co. Ltd. · primary completion: 2026-04-30 → 2026-09-23; date type: ESTIMATED → ACTUAL; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 165 → 181 FIRMED · Lumason® Infusion vs. Bolus Administrationshttps://saros.gcarosso.bio/#t=NCT06400004NCT06400004:firmed:2026-10-20Bracco Diagnostics, Inc · primary completion: 2026-05-31 → 2026-08-29; date type: ESTIMATED → ACTUAL STATUS · A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breahttps://saros.gcarosso.bio/#t=NCT07153159NCT07153159:status:2026-10-20Pfizer · status: ACTIVE_NOT_RECRUITING → COMPLETED FIRMED · Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitishttps://saros.gcarosso.bio/#t=NCT03989206NCT03989206:firmed:2026-10-20Galderma R&D · date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED; enrollment: 1700 → 1935 NEW · A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).https://saros.gcarosso.bio/#t=NCT07883590NCT07883590:new:2026-10-20Eli Lilly and Company · new in the registry NEW · Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Vihttps://saros.gcarosso.bio/#t=NCT07881991NCT07881991:new:2026-10-20CSPC Ouyi Pharmaceutical Co., Ltd. · new in the registry NEW · Safety of CRT100 on Treatment Spinal Cord Injuryhttps://saros.gcarosso.bio/#t=NCT05739734NCT05739734:new:2026-10-20Cristália Produtos Químicos Farmacêuticos Ltda. · new in the registry SLIPPED · Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combinathttps://saros.gcarosso.bio/#t=NCT06533761NCT06533761:slipped:2026-10-20Stelexis BioSciences · primary completion: 2027-07-15 → 2027-12-15; enrollment: 125 → 105 SLIPPED · Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDDhttps://saros.gcarosso.bio/#t=NCT06828887NCT06828887:slipped:2026-10-20Vigonvita Life Sciences · primary completion: 2026-09-01 → 2027-09-01 FIRMED · A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Diseasehttps://saros.gcarosso.bio/#t=NCT06603246NCT06603246:firmed:2026-10-20Genentech, Inc. · primary completion: 2027-11-15 → 2026-08-18; date type: ESTIMATED → ACTUAL; status: RECRUITING → TERMINATED; enrollment: 128 → 17; why stopped: → Sponsor's Decision NEW · Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)https://saros.gcarosso.bio/#t=NCT07881952NCT07881952:new:2026-10-20Verrica Pharmaceuticals Inc. · new in the registry STATUS · Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)https://saros.gcarosso.bio/#t=NCT07486960NCT07486960:status:2026-10-20Merck Sharp & Dohme LLC · primary completion: 2027-08-13 → 2027-02-17; status: RECRUITING → ACTIVE_NOT_RECRUITING SLIPPED · Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancieshttps://saros.gcarosso.bio/#t=NCT04561362NCT04561362:slipped:2026-10-20BicycleTx Limited · primary completion: 2026-03 → 2027-01 FIRMED · HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.https://saros.gcarosso.bio/#t=NCT07233070NCT07233070:firmed:2026-10-20Fujian Shengdi Pharmaceutical Co., Ltd. · primary completion: 2026-10 → 2026-09-17; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED FIRMED · A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination Withttps://saros.gcarosso.bio/#t=NCT05952037NCT05952037:firmed:2026-10-20BeOne Medicines · date type: ESTIMATED → ACTUAL CHANGED · Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Muhttps://saros.gcarosso.bio/#t=NCT04856982NCT04856982:changed:2026-10-20Biogen · primary outcome text: Parts B and C: Percentage of Participants with Emergence of Clinically Manifest ALS Within 24 Months of Part B Baseline → Part B: Time to Emergence of Clinically Manifest ALS SLIPPED · A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advancehttps://saros.gcarosso.bio/#t=NCT05544929NCT05544929:slipped:2026-10-20Novartis Pharmaceuticals · primary completion: 2027-09-01 → 2027-10-05 NEW · MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumorshttps://saros.gcarosso.bio/#t=NCT06586515NCT06586515:new:2026-10-20Eli Lilly and Company · new in the registry SLIPPED · A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Diseasehttps://saros.gcarosso.bio/#t=NCT07571746NCT07571746:slipped:2026-10-20AstraZeneca · primary completion: 2028-04-24 → 2028-10-13 STATUS · A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areatahttps://saros.gcarosso.bio/#t=NCT07762443NCT07762443:status:2026-10-20Jiangsu vcare pharmaceutical technology co., LTD · status: NOT_YET_RECRUITING → RECRUITING STATUS · A Study of SHR-1918 In Participants With Hypertriglyceridemiahttps://saros.gcarosso.bio/#t=NCT07349615NCT07349615:status:2026-10-20Beijing Suncadia Pharmaceuticals Co., Ltd · primary completion: 2027-11 → 2027-03; status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 360 → 367 FIRMED · A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinomahttps://saros.gcarosso.bio/#t=NCT05888844NCT05888844:firmed:2026-10-20Incyte Corporation · date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → This was a strategic business decision. There were no safety concerns contributing to this decision. NEW · A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHThttps://saros.gcarosso.bio/#t=NCT07882654NCT07882654:new:2026-10-20EktaH · new in the registry STATUS · A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults https://saros.gcarosso.bio/#t=NCT07792941NCT07792941:status:2026-10-20Pfizer · primary completion: 2027-02-11 → 2027-02-20; status: RECRUITING → ACTIVE_NOT_RECRUITING CHANGED · A Study of V132 in Healthy Older Participants (V132-001)https://saros.gcarosso.bio/#t=NCT07712575NCT07712575:changed:2026-10-20Merck Sharp & Dohme LLC · primary completion: 2028-06-21 → 2028-05-05 FIRMED · A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumorshttps://saros.gcarosso.bio/#t=NCT06257264NCT06257264:firmed:2026-10-20BeiGene · primary completion: 2026-08-31 → 2026-08-27; date type: ESTIMATED → ACTUAL SLIPPED · A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumorshttps://saros.gcarosso.bio/#t=NCT05585320NCT05585320:slipped:2026-10-20Immuneering Corporation · primary completion: 2026-06 → 2027-06 FIRMED · Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially https://saros.gcarosso.bio/#t=NCT07398378NCT07398378:firmed:2026-10-20Colgate Palmolive · primary completion: 2026-07 → 2026-07-05; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED SLIPPED · A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirhttps://saros.gcarosso.bio/#t=NCT07652723NCT07652723:slipped:2026-10-20Bayer · primary completion: 2026-12-29 → 2027-03-10 STATUS · A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malihttps://saros.gcarosso.bio/#t=NCT05957367NCT05957367:status:2026-10-20Deciphera Pharmaceuticals, LLC · status: RECRUITING → ACTIVE_NOT_RECRUITING FIRMED · Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancerhttps://saros.gcarosso.bio/#t=NCT04736173NCT04736173:firmed:2026-10-19Arcus Biosciences, Inc. · primary completion: 2027-05 → 2026-09-17; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → COMPLETED NEW · A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problemshttps://saros.gcarosso.bio/#t=NCT07881757NCT07881757:new:2026-10-19Pfizer · new in the registry STATUS · A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participanthttps://saros.gcarosso.bio/#t=NCT07715747NCT07715747:status:2026-10-19TJ Biopharma Co., Ltd. · status: NOT_YET_RECRUITING → RECRUITING SLIPPED · SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinomahttps://saros.gcarosso.bio/#t=NCT07254585NCT07254585:slipped:2026-10-19CSPC Megalith Biopharmaceutical Co.,Ltd. · primary completion: 2026-06-30 → 2028-06-30; enrollment: 70 → 110 STATUS · A Study With CIT-013 in HS Patientshttps://saros.gcarosso.bio/#t=NCT06993233NCT06993233:status:2026-10-19Citryll BV · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 96 → 108 NEW · Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesishttps://saros.gcarosso.bio/#t=NCT06836557NCT06836557:new:2026-10-19Vanda Pharmaceuticals · new in the registry CHANGED · A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy ohttps://saros.gcarosso.bio/#t=NCT03854110NCT03854110:changed:2026-10-19Persevere Therapeutics Inc. · enrollment: 80 → 18 STATUS · Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumhttps://saros.gcarosso.bio/#t=NCT05800964NCT05800964:status:2026-10-19Amgen · status: COMPLETED → TERMINATED; why stopped: → Sponsor decision STATUS · Software as a Medical Device for the Treatment of Patients With PTSDhttps://saros.gcarosso.bio/#t=NCT06589505NCT06589505:status:2026-10-19Otsuka Medical Devices Co., Ltd. Japan · status: RECRUITING → ACTIVE_NOT_RECRUITING NEW · Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attribuhttps://saros.gcarosso.bio/#t=NCT07880756NCT07880756:new:2026-10-19AbbVie · new in the registry STATUS · A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Wayshttps://saros.gcarosso.bio/#t=NCT07837648NCT07837648:status:2026-10-19Boehringer Ingelheim · status: NOT_YET_RECRUITING → RECRUITING STATUS · KN035 for dMMR/MSI-H Advanced Solid Tumorshttps://saros.gcarosso.bio/#t=NCT03667170NCT03667170:status:2026-10-193D Medicines (Sichuan) Co., Ltd. · status: RECRUITING → ACTIVE_NOT_RECRUITING; enrollment: 200 → 188 FIRMED · PET-Based Imaging of Radiolabeled CIT-013https://saros.gcarosso.bio/#t=NCT07147959NCT07147959:firmed:2026-10-19Citryll BV · primary completion: 2026-10-01 → 2026-07-15; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 12 → 7 STATUS · A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulationhttps://saros.gcarosso.bio/#t=NCT07813039NCT07813039:status:2026-10-19Vertex Pharmaceuticals Incorporated · status: NOT_YET_RECRUITING → RECRUITING NEW · A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus https://saros.gcarosso.bio/#t=NCT07881705NCT07881705:new:2026-10-19Jiangsu Simcere Pharmaceutical Co., Ltd. · new in the registry SLIPPED · Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumhttps://saros.gcarosso.bio/#t=NCT03891953NCT03891953:slipped:2026-10-19Novartis Pharmaceuticals · primary completion: 2026-10-30 → 2027-06-25 FIRMED · A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Oldhttps://saros.gcarosso.bio/#t=NCT07722585NCT07722585:firmed:2026-10-19Bayer · primary completion: 2026-10-07 → 2026-10-12; date type: ESTIMATED → ACTUAL; status: RECRUITING → COMPLETED; enrollment: 18 → 16 FIRMED · A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanomahttps://saros.gcarosso.bio/#t=NCT05529316NCT05529316:firmed:2026-10-19Agenus Inc. · primary completion: 2028-02 → 2026-04-27; date type: ESTIMATED → ACTUAL; status: ACTIVE_NOT_RECRUITING → TERMINATED; why stopped: → Sponsor decision STATUS · QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patihttps://saros.gcarosso.bio/#t=NCT07716449NCT07716449:status:2026-10-19Qilu Pharmaceutical Co., Ltd. · status: NOT_YET_RECRUITING → RECRUITING; primary outcome text: Progression free survival (PFS) → OS CHANGED · Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Ovhttps://saros.gcarosso.bio/#t=NCT07166081NCT07166081:changed:2026-10-19BrightGene Bio-Medical Technology Co., Ltd. · primary completion: 2026-05-13 → 2026-03-16